baseclick GmbH is a biotechnological company and experts in nucleic acid modification. In spring 2020 the company was starting to develop an mRNA-based vaccine to combat the COVID-19 pandemic.

In the last years, the team of Dr. Thomas Frischmuth at baseclick GmbH advanced the click chemistry for the modification of messenger RNA (mRNA) for the application of individualized cancer therapy as well as the treatment of rare diseases. This promising worldwide patented click technology is now to be incorporated into the development of a corona vaccine.

The company was founded in 2008 as a spin out of the Ludwig-Maximilian University in Munich by Prof. Dr. Thomas Carell. With the so-called “click chemistry”, discovered by the Nobel laureate in chemistry Prof. Dr. Barry Sharpless, baseclick GmbH has developed a wide variety of nucleic acid modifications. baseclick GmbH, based in Neuried, has out-licensed this technology to numerous leading companies worldwide.

Initial investment:

B2G Partner:
Thomas Villinger


Spin-out of the Ludwig-Maximilian University Munich by Prof. Dr. Carell
Second round financing by private investors
Outlicensing of the click chemistry Technology to Oligo producers and Life technologies

Life Technologies was acquired by Thermo Fisher Scientific in January, 2014

ISO-9001-2008 certification
distribution contracts with Merck Millipore, Sigma Aldrich and Carl Roth
relocation from Tutzingen to Neuried
Outlicensing of the click chemistry Technology to Pacific Bioscience for Next Generation Sequencing (NGS) applications and ISO-9001:2015 certification
Launch of the mRNA labeling- and transfection kit
Cooperation with the University of Groningen and the University Hospital Eppendorf in Hamburg in development of mRNA-based cancer medications and for the treatment of rare diseases
starting to develop a vaccine to combat the COVID-19 pandemic and launch of the NGS-mRNA-preparation kits

“I am very grateful that BORN2GROW has expressed its trust in the baseclick team and made the start of the development of a vaccine against SARS-CoV-2 possible at baseclick.”

Dr. Thomas Frischmuth